Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell Lines

15 Jan 1992

Abstract excerpt

BACKGROUND: Small-cell lung cancer (SCLC) is more sensitive to anticancer agents than non-small-cell lung cancer (NSCLC), but few studies have analyzed the mechanisms of natural drug resistance responsible for this difference. PURPOSE: To elucidate these mechanisms, we determined drug sensitivity and evaluated the biochemical parameters affecting response to the DNA topoisomerase II inhibitors doxorubicin and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1310509
DOI: 10.1093/jnci/84.2.113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell LinesPMID 1310509Read ↗

Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs.Semantic proximity Read ↗

Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.Semantic proximity Read ↗

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.Semantic proximity Read ↗

TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to TopotecanSemantic proximity Read ↗

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with CisplatinSemantic proximity Read ↗

Drug resistance in lung cancerSemantic proximity Read ↗

<p>A novel mutation panel for predicting etoposide resistance in small-cell lung cancer</p>Semantic proximity Read ↗

Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell linesSemantic proximity Read ↗

Treatment with the Chk1 inhibitor Gï¿½6976 enhances cisplatin cytotoxicity in SCLC cellsSemantic proximity Read ↗

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancerSemantic proximity Read ↗

p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.Semantic proximity Read ↗

Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.